Characteristics of patients with pituitary gigantism : results of an international study

in Endocrine abstracts - 15th European Congress of Endocrinology (2013, May)

The clinical and genetic characteristics of patients with gigantism

in Abstract Book - 13th International Workshop on Multiple Endocrine Neoplasia (2012, September)

Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas - An International Collaborative Study

in Journal of Clinical Endocrinology and Metabolism (2010), 95(11),

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features ... [more ▼]

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. [less ▲]

Caractéristiques cliniques et réponses thérapeutiques des patients avec adénome hypophysaire mutés pour AIP : étude internationale sur 96 cas

in Annales d'Endocrinologie (2010, September), 71(5), 346

High Prevalence of AIP Gene Mutations Following Focussed Screening in Young Patients with Sporadic Pituitary Macroadenomas

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

pasireotide LAR is effective in patients <ith acromegaly : interim results from a randomized, multicenter, pharmacokinetic/pharmacodynamic, Phase I Study

in ENDO 2008: 90th Annual Meeting of the Endocrine Society - Abstract book (2008)

Monoclonal Antibodies To Growth Hormone (Gh) Prolong Liver Gh Binding And Gh-Induced Igf-I/Igfbp-3 Synthesis

in American Journal of Physiology - Endocrinology and Metabolism (1999), 277(2),

Effects of growth hormone therapy on bone metabolism in patients with adult-onset : a 2-year open randomized controlled multicentre trial

in The 6th International Pituitary Congress - Abstract book (1999)

Monoclonal antibodies against bovine growth hormone (bGH) enhance the biological response to GH by prolonging GH binding to its liver receptors.

in Endocrinology (1995), 136(Suppl 1), 344